IXC 0.00% 8.2¢ invex therapeutics ltd

Fifty one capital podcast episode on Invex, page-6

  1. 335 Posts.
    lightbulb Created with Sketch. 147
    Yep, would imagine people taking positions. It's less than a month away from Phase 2 results. If it's a success, it's one pivotal registration trial(and PK study) away from coming to market in the US and EU.

    If you assume as Fifty One Capital have done; that Presendin will take a 40% share of the Total Addressable Market of $1.6B. Then peak sales are $640 million. Attach a 3-4 multiplier in terms of valuation, and you're left with a possible transaction value of $2B+ for the IIH product alone.

    Lots of assumptions in the model, but at a $60 million market cap, it's becoming a very attractive proposition for long term investors.
    Last edited by arkangel256: 28/04/20
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.